Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Short Interest Update

Key Points

• Short interest in Nanobiotix S.A. has surged by 209.8%, increasing from 6,100 shares to 18,900 shares as of July 31st, resulting in a short-interest ratio of 2.4 days.
• On July 31st, Nanobiotix's stock price fell 3.5% to $7.91, while its 52-week range has been between $2.76 and $8.47.
• Institutional investors now own 38.81% of Nanobiotix's stock, with recent stakes purchased by Geode Capital Management, Millennium Management, and Jane Street Group, valued at approximately $29,000, $39,000, and $73,000, respectively.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 18,900 shares, agrowthof209.8% from the July 15th total of 6,100 shares. Currently,0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 7,900 shares, the short-interest ratio is currently 2.4 days. Based on an average daily trading volume, of 7,900 shares, the short-interest ratio is currently 2.4 days. Currently,0.0% of the shares of the stock are short sold.

Nanobiotix Trading Up 14.2%

Nanobiotix stock traded up $1.21 during trading hours on Thursday, reaching $9.74. 35,251 shares of the stock were exchanged, compared to its average volume of 13,354. Nanobiotix has a twelve month low of $2.76 and a twelve month high of $9.80. The stock has a 50 day moving average of $5.93 and a two-hundred day moving average of $4.43.

Institutional Investors Weigh In On Nanobiotix

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC bought a new stake in shares of Nanobiotix during the fourth quarter worth $29,000. Millennium Management LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at $39,000. Finally, Jane Street Group LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at $73,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.